Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Sharpens Injectables Business With Agila Buy For $1.6 Billion

This article was originally published in The Pink Sheet Daily

Executive Summary

Stream of highly profitable drug launches in the U.S. by India’s Agila attracted Mylan to make an aggressive bid, leapfrogging it from the bottom 10 rank to a leading position in the injectables space. Drug shortages add to Mylan opportunity in bringing in Agila’s injectables. Deal includes added $250 million in potential milestone payments.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel